Challenges And Opportunities At The New Cytiva
CEO Emmanuel Ligner Outlines Future At Biopharma’s Biggest Manufacturing Business
Executive Summary
In 2019, more than 75% of the biological therapies approved by the FDA used technologies developed by GE Healthcare Life Sciences for manufacturing. Following the completion of a $21.9bn acquisition by Danaher, the company has rebranded to Cytiva. In Vivo speaks with CEO Emmanuel Ligner to learn more about his vision for the new company and the impact of COVID-19.
You may also be interested in...
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
Abbott Surprises Analysts With CE Mark For Freestyle Libre 3
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.